Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 245

1.

Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection.

Charalampous T, Kay GL, Richardson H, Aydin A, Baldan R, Jeanes C, Rae D, Grundy S, Turner DJ, Wain J, Leggett RM, Livermore DM, O'Grady J.

Nat Biotechnol. 2019 Jul;37(7):783-792. doi: 10.1038/s41587-019-0156-5. Epub 2019 Jun 24.

PMID:
31235920
2.

Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections.

Horner C, Mushtaq S, Livermore DM; BSAC Resistance Surveillance Standing Committee .

J Antimicrob Chemother. 2019 Jul 1;74(7):1940-1944. doi: 10.1093/jac/dkz133.

PMID:
31032858
3.

Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?-authors' response.

Russell AH, Horner C, Livermore DM, MacGowan AP.

J Antimicrob Chemother. 2019 Jun 1;74(6):1767. doi: 10.1093/jac/dkz105. No abstract available.

PMID:
30915460
4.

Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae.

Mushtaq S, Vickers A, Woodford N, Haldimann A, Livermore DM.

J Antimicrob Chemother. 2019 Apr 1;74(4):953-960. doi: 10.1093/jac/dky522.

PMID:
30590470
5.

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.

Edgeworth JD, Merante D, Patel S, Young C, Jones P, Vithlani S, Wyncoll D, Roberts P, Jones A, Den Nagata T, Ariyasu M, Livermore DM, Beale R.

Clin Infect Dis. 2019 May 17;68(11):1932-1934. doi: 10.1093/cid/ciy963.

6.

OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producing Escherichia coli.

Livermore DM, Day M, Cleary P, Hopkins KL, Toleman MA, Wareham DW, Wiuff C, Doumith M, Woodford N.

J Antimicrob Chemother. 2019 Feb 1;74(2):326-333. doi: 10.1093/jac/dky453.

PMID:
30388219
7.

The 2018 Garrod Lecture: Preparing for the Black Swans of resistance.

Livermore DM.

J Antimicrob Chemother. 2018 Nov 1;73(11):2907-2915. doi: 10.1093/jac/dky265.

PMID:
30351434
8.

Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae.

Livermore DM, Mushtaq S, Doumith M, Jamrozy D, Nichols WW, Woodford N.

J Antimicrob Chemother. 2018 Dec 1;73(12):3336-3345. doi: 10.1093/jac/dky363.

PMID:
30247546
9.

Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?

Russell AH, Horner C, Livermore DM, MacGowan AP.

J Antimicrob Chemother. 2018 Nov 1;73(11):3212-3215. doi: 10.1093/jac/dky306. No abstract available.

PMID:
30085229
10.

Activity of RX-04 Pyrrolocytosine Protein Synthesis Inhibitors against Multidrug-Resistant Gram-Negative Bacteria.

Vickers A, Mushtaq S, Woodford N, Doumith M, Livermore DM.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00689-18. doi: 10.1128/AAC.00689-18. Print 2018 Aug.

11.

Pseudomonas aeruginosa sequence type 357 with VEB extended-spectrum β-lactamases in the UK: relatedness and resistance.

Greenwood B, Meunier D, Hopkins KL, Pike R, Ivanov Z, Turton JF, Hill R, Woodford N, Livermore DM.

Int J Antimicrob Agents. 2018 Aug;52(2):301-302. doi: 10.1016/j.ijantimicag.2018.03.013. Epub 2018 Mar 23. No abstract available.

PMID:
29580931
12.

Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party.

Hawkey PM, Warren RE, Livermore DM, McNulty CAM, Enoch DA, Otter JA, Wilson APR.

J Antimicrob Chemother. 2018 Mar 1;73(suppl_3):iii2-iii78. doi: 10.1093/jac/dky027. Review.

PMID:
29514274
13.

The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.

Hammond M, Clark AB, Cahn AP, Chilvers ER, Fraser WD, Livermore DM, Maher TM, Parfrey H, Swart AM, Stirling S, Thickett D, Whyte M, Wilson A.

Trials. 2018 Feb 5;19(1):89. doi: 10.1186/s13063-018-2453-6.

14.

Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.

Livermore DM, Meunier D, Hopkins KL, Doumith M, Hill R, Pike R, Staves P, Woodford N.

J Antimicrob Chemother. 2018 Mar 1;73(3):648-657. doi: 10.1093/jac/dkx438.

PMID:
29228202
15.

Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance.

Doumith M, Mushtaq S, Martin V, Chaudhry A, Adkin R, Coelho J, Chalker V, MacGowan A, Woodford N, Livermore DM; BSAC Resistance Surveillance Standing Committee.

J Antimicrob Chemother. 2017 Oct 1;72(10):2704-2707. doi: 10.1093/jac/dkx207.

PMID:
29091185
16.

Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens.

Livermore DM, Mushtaq S, Warner M, Turner SJ, Woodford N.

J Antimicrob Chemother. 2018 Jan 1;73(1):126-133. doi: 10.1093/jac/dkx360.

PMID:
29059308
17.

AmpC β-lactamase induction by avibactam and relebactam.

Livermore DM, Jamrozy D, Mushtaq S, Nichols WW, Young K, Woodford N.

J Antimicrob Chemother. 2017 Dec 1;72(12):3342-3348. doi: 10.1093/jac/dkx298.

PMID:
28962008
18.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model.

VanScoy BD, Tenero D, Turner S, Livermore DM, McCauley J, Conde H, Bhavnani SM, Rubino CM, Ambrose PG.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01052-17. doi: 10.1128/AAC.01052-17. Print 2017 Dec.

19.

Assessment of the Target Engagement and D-Serine Biomarker Profiles of the D-Amino Acid Oxidase Inhibitors Sodium Benzoate and PGM030756.

Howley E, Bestwick M, Fradley R, Harrison H, Leveridge M, Okada K, Fieldhouse C, Farnaby W, Canning H, Sykes AP, Merchant K, Hazel K, Kerr C, Kinsella N, Walsh L, Livermore DG, Hoffman I, Ellery J, Mitchell P, Patel T, Carlton M, Barnes M, Miller DJ.

Neurochem Res. 2017 Nov;42(11):3279-3288. doi: 10.1007/s11064-017-2367-9. Epub 2017 Aug 5.

PMID:
28780732
20.

1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction.

Ahmed S, Ayscough A, Barker GR, Canning HE, Davenport R, Downham R, Harrison D, Jenkins K, Kinsella N, Livermore DG, Wright S, Ivetac AD, Skene R, Wilkens SJ, Webster NA, Hendrick AG.

J Med Chem. 2017 Jul 13;60(13):5663-5672. doi: 10.1021/acs.jmedchem.7b00352. Epub 2017 Jun 24.

PMID:
28594552

Supplemental Content

Loading ...
Support Center